Allmed Solutions Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -0.241x

Allmed Solutions Ltd cash flow conversion efficiency. Based on the latest financial reports, Allmed Solutions Ltd (ALMD) has a cash flow conversion efficiency ratio of -0.241x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-6.77 Million ≈ $-18.14K USD) by net assets (ILA28.07 Million ≈ $75.25K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Allmed Solutions Ltd (2008–2025)

Cash flow conversion efficiency of Allmed Solutions Ltd from 2008 to 2025. This chart illustrates how Allmed Solutions Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALMD stock price and chart for real-time trading data and today's change.

Allmed Solutions Ltd Cash Flow Conversion Ratio Explained

Allmed Solutions Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Allmed Solutions Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Allmed Solutions Ltd ranked by their cash flow conversion efficiency. Also see Allmed Solutions Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Tay Ninh Cable Car Tour Co.
VN:TCT
-0.003x
Melbana Energy Ltd
AU:MAY
-0.017x
Korea Plasma Technology U Co.Ltd
KQ:054410
0.004x
Wise Group AB
ST:WISE
0.075x
Oxford BioMedica PLC
LSE:OXB
0.072x
Nimy Resources Ltd
AU:NIM
-0.130x
Focus Dynamics Group Bhd
KLSE:0116
0.047x
Green Technology Metals Ltd
AU:GT1
-0.017x

Annual Cash Flow Conversion Efficiency for Allmed Solutions Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of Allmed Solutions Ltd from 2008 to 2025. Review free cash flow generation of Allmed Solutions Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ILA28.07 Million
≈ $75.25K
ILA-12.08 Million
≈ $-32.39K
-0.430x -125.38%
2024-12-31 ILA42.02 Million
≈ $112.65K
ILA-8.03 Million
≈ $-21.51K
-0.191x -249.81%
2023-12-31 ILA55.97 Million
≈ $150.06K
ILA7.14 Million
≈ $19.13K
0.127x +167.35%
2022-12-31 ILA53.96 Million
≈ $144.67K
ILA-10.21 Million
≈ $-27.39K
-0.189x -80.81%
2021-12-31 ILA52.31 Million
≈ $140.25K
ILA-5.48 Million
≈ $-14.68K
-0.105x +42.08%
2020-12-31 ILA48.77 Million
≈ $130.76K
ILA-8.82 Million
≈ $-23.64K
-0.181x +17.04%
2019-12-31 ILA56.58 Million
≈ $151.69K
ILA-12.33 Million
≈ $-33.05K
-0.218x +55.35%
2018-12-31 ILA32.83 Million
≈ $88.02K
ILA-16.02 Million
≈ $-42.96K
-0.488x -2.71%
2017-12-31 ILA38.76 Million
≈ $103.91K
ILA-18.42 Million
≈ $-49.38K
-0.475x -5.08%
2016-12-31 ILA38.19 Million
≈ $102.39K
ILA-17.27 Million
≈ $-46.30K
-0.452x -28.55%
2015-12-31 ILA45.13 Million
≈ $120.98K
ILA-15.87 Million
≈ $-42.56K
-0.352x +40.54%
2014-12-31 ILA32.16 Million
≈ $86.22K
ILA-19.03 Million
≈ $-51.01K
-0.592x -33.36%
2013-12-31 ILA30.22 Million
≈ $81.02K
ILA-13.41 Million
≈ $-35.94K
-0.444x -1.62%
2012-12-31 ILA67.29 Million
≈ $180.40K
ILA-29.37 Million
≈ $-78.75K
-0.437x -141.17%
2011-12-31 ILA72.36 Million
≈ $193.98K
ILA-13.10 Million
≈ $-35.11K
-0.181x +43.58%
2010-12-31 ILA26.29 Million
≈ $70.47K
ILA-8.43 Million
≈ $-22.61K
-0.321x -102.04%
2009-12-31 ILA10.83 Million
≈ $29.04K
ILA-1.72 Million
≈ $-4.61K
-0.159x +61.70%
2008-12-31 ILA14.19 Million
≈ $38.04K
ILA-5.88 Million
≈ $-15.77K
-0.415x --

About Allmed Solutions Ltd

TA:ALMD Israel Medical Devices
Market Cap
$8.01 Million
ILA2.99 Billion ILA
Market Cap Rank
#27482 Global
#389 in Israel
Share Price
ILA31.10
Change (1 day)
+0.00%
52-Week Range
ILA26.60 - ILA40.50
All Time High
ILA186.00
About

Allmed Solutions Ltd develops, manufactures, and markets minimally invasive products in various medical disciplines in Israel and internationally. The company offers drugs, biological products, and medical devices; and ProCatid system, a distal embolic protection system comprised of an independent filter unit that can be delivered, locked, and deployed on any commercially marketed guide wires. It… Read more